ARCHIVES
VOL. 10, ISSUE 2 (2025)
Immune response and therapies involved in colorectal cancer (CRC)
Authors
Janhavi Rai, Manvee Rai
Abstract
Colorectal cancer (CRC) is one of the third most common cancer in the
world. Most of the ceases of CRC is detected in the western countries. The risk
of developing colorectal cancer is approximately 4-5%. The front-line treatment
is dose-limiting toxicities often occur in colorectal cancer, including
chemotherapy and radiation therapy in CRC patients which is beneficial for the
patient mortality rate, but because of the slows treatment progression and slow
therapeutic effect the chemotherapy and radiation therapy is not satisfactory;
hence immunotherapy came into the picture. Immunotherapy includes treatment
with antibodies, or small molecules to activate the immune system for
deteriorating the cancer cell. The clinical research on colorectal cancer
immunotherapy includes immune checkpoints, anti- immune checkpoint, monoclonal
antibodies, cancer vaccines and immune system modulators. This review describes
the preclinical clinical trial investigating the immune response of CRC
patients and various others therapy for treatment and prognosis of colorectal
cancer biomarkers of response to these treatments.
Download
Pages:12-18
How to cite this article:
Janhavi Rai, Manvee Rai "Immune response and therapies involved in colorectal cancer (CRC)". International Journal of Advanced Scientific Research, Vol 10, Issue 2, 2025, Pages 12-18
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.